EOS Imaging (Formerly Known as biospace med) Release: Acceleration in Overseas Sales Momentum
Published: Jun 11, 2012
EOS imaging is pursuing its sales strategy in Asia via Singapore, a cutting-edge market and a showcase for the Southeast Asia zone. EOS imaging has chosen QST Group, a leader in the distribution of medical equipment with substantial experience in innovative medical materials, notably in the field of orthopedic surgery (with Bbraun) and imaging (with, amongst others, Philips). The distribution agreement that has just been signed will enable QST to offer a revolutionary orthopedic imaging solution that meets the requirements of the Singapore market, and will enable EOS imaging to deploy its technology in Southeast Asia.
In the United States, in parallel, EOS imaging has expanded its sales presence with the signature of agent partnerships with two new networks of commercial agents to supplement its current network by initiating a presence in 13 more states in the midwest and west. The Group now covers almost all of the United States.
Marie Meynadier, CEO of EOS imaging, states: “We are delighted with the signing of this distribution contract with QST Group, which confirms the quality of our offer and will enable us to extend our sales presence in a high- potential region with growing demand for orthopedic surgery. This agreement marks a first major step in the roadmap presented at the time of our IPO. We are also pursuing our sales strategy with the signature of two more commercial agent contracts in the United States, and are accelerating the structuring of our commercial organization around the world, and in particular in countries with strong demand for medical equipment such as the United States.”
About EOS imaging
The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EC). Thanks to an installed base of 47 sites and more than 150,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 57 people including an R&D team of 21 engineers and recorded consolidated revenue of €6.9 million in 2011. The Group's head office is based in Paris, with a subsidiary in the United States at Cambridge, Massachusetts, as well as offices in Montreal (Canada) and Germany.
Further information about EOS imaging can be found at the following site: www.eos-imaging.com
EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: revenue for the first half of 2012, 25 July 2012 (after market).
Tel.: +33 (0)1 55 25 61 24
Financial communication and investor relations
Sophie Boulila / Pierre Laurent
Tel.: +33(0)1 44 71 94 91 – firstname.lastname@example.org
Caroline Carmagnol / Anne-Sophie Cosquéric
Tel : +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59
email@example.com / firstname.lastname@example.org